Microfluidic device for multimodal char

sly ten A) n o do ve in as d le v nst erf lity cti II DM, insulin secretion is damaged because of glucotoxicity and lipotoxicity. For Type I DM, maintaining blood glucose levels assay provide us with little information about b-cell function and morphology, metabolism, and of isolated islets to diabetic s an in vivo model to assess the lanted islets to reverse DM). oportion of mice in which DM batch of islets. This potency olerance tests allows the effi-recipient to be predicted, but ouse model takes as long as l to develop a standardized, b-cell function based on b-cell old standard for assessing the post isolation prior to trans-resent the design, fabrication, and testing of a microfluidic device for multiplexing several well-PAPER www.rsc.org/loc | Lab on a ChipChicago, Chicago, IL, USAfrom multiple donors using steroid-free, sirolimus based immu-nosuppression.51 With the new protocol, islet transplantation accepted islet functional assays. Temporally resolved analysis of the kinetics of insulin secre-tion, mitochondria potential, and [Ca2+]i will provide in depth understanding of the functionality of the islets. While all of these assays can currently be multiplexed in a 96-well plate, these experiments rely on static incubation of the islets. The static analysis of islets can not provide the details on temporal dynamics of insulin secretion of islets and therefore necessitate